Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

CSF1R inhibition could delay muscular dystrophy progression

July 1, 2022

Tuojie Biotech identifies new P2X3 antagonists

July 1, 2022

IAMA reports responses with selective NKCC1 inhibitors in animal models of Down syndrome and autism

June 30, 2022

Palacky University patents new terpenoid derivatives

June 30, 2022

Myelin-forming cells change in multiple brain diseases

June 29, 2022

FABP5 inhibitor ART26.12 shows promise for chemotherapy-induced pain

June 29, 2022

Wellstat Therapeutics divulges novel uridine derivatives

June 29, 2022

EAN 2022: At several scales, connective landscape provides lens for neurology

June 28, 2022

MagicMed Industries discloses new 5-HT2A receptor agonists

June 28, 2022

SAGE Therapeutics describes new GABA-A receptor modulators

June 27, 2022

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 17, 2026.
ALN-5288 lowers tau levels in preclinical models
BioWorld Science
Pathological tau accumulation is a key driver of neurodegeneration in Alzheimer’s disease (AD) and other tauopathies such as progressive supranuclear palsy....
Dual FAAH/MAGL inhibition targets Alzheimer’s disease hyperexcitability
BioWorld Science
Reduced endocannabinoid signaling has been linked to neuronal hyperexcitability in Alzheimer’s disease (AD), suggesting that dual inhibition of fatty acid amide...
Capital remains selective in ‘barbell’ biotech market
BioWorld
Signs of recovery are emerging in the biotechnology investment sector, although investors across Asia say that capital is flowing selectively to companies that...
PSB-229 reduces plaque burden in Alzheimer’s models
BioWorld Science
Pyroglutamate-modified amyloid-β (pE3-Aβ) is a highly pathogenic Aβ species that accumulates within amyloid plaques and contributes to aggregation,...